Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (18638)	1/4/2006 11:19:30 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

Cambrex Revises Strategic Direction and Announces Senior Management Transition Plan Wednesday January 4, 11:00 am ET EAST RUTHERFORD, N.J., Jan. 4 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM - News) announced today that its Board of Directors has decided to discontinue the Company's acquisition program aimed at transforming Cambrex into a specialty therapeutics enterprise due to the increasing cost to acquire companies in this sector coupled with the risk of achieving an appropriate return on investment. In order to maximize shareholder value, the Company will concentrate its resources going forward on the Bioproducts segment and capitalize on its leadership positions in cell biology, molecular biology, rapid microbial testing and cell therapy manufacturing. The Human Health and Biopharma segments will continue to be allocated the appropriate resources necessary to maintain their leading market positions.